Cavadex America

Cavadex AmericaCavadex AmericaCavadex America
Home
About
Products
Videos
Research

Cavadex America

Cavadex AmericaCavadex AmericaCavadex America
Home
About
Products
Videos
Research
More
  • Home
  • About
  • Products
  • Videos
  • Research
  • Sign In
  • Create Account

  • Orders
  • My Account
  • Signed in as:

  • filler@godaddy.com


  • Orders
  • My Account
  • Sign out


Signed in as:

filler@godaddy.com

  • Home
  • About
  • Products
  • Videos
  • Research

Account


  • Orders
  • My Account
  • Sign out


  • Sign In
  • Orders
  • My Account

Research

 

2013

5a. We know HP-B-CD is safe to use on humans....

A human trial was conducted on twin girls suffering from Niemann-Pick disease.
High dose HP-B-CD was administered via IV for over 2 years to remove cholesterol from cells.

Effects of cyclodextrin in two patients with Niemann–Pick Type C disease

https://www.sciencedirect.com/science/article/abs/pii/S1096719212004155

2016

5b. We know HP-B-CD removes arterial plaque from mice....

Scientists from Bonn university, Germany, trialed HP-B-CD on mice with atherosclerosis
and discovered that HP-B-CD substantially reduced the atherosclerotic plaque.

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878149/

2019

5c. We know HP-B-CD reduces arterial plaque from humans....

After concluding that the science behind HP-B-CD showed that it was safe on humans and HP-B-CD successfully
reduced arterial plaque in mice, Kyle Hodgetts established the company Cholrem Pty Ltd and did
a trial on himself using HP-B-CD to reduce his arterial plaque, resulting in substantial plaque reduction.

2-hydroxypropyl-β-cyclodextrin reduces atherosclerotic plaques in human coronary artery

Peer reviewed published paper - from our 2019 trial

2021

5d. We know Cavadex reduces arterial plaque and improves lipid profile and liver function....

After the success of the first trial, Cholrem Pty Ltd developed a version of HP-B-CD “CAVADEX” and Kyle did a second trial on himself using Cavadex,
resulting in substantial lipid reduction, improved liver function and reduced arterial plaque.
Kyle consulted with Australian Professor Laurie Howes MB BS PhD FRACP FCSANZ (Head of cardiovascular research at one of Australia’s
largest hospitals. Preeminent Consultant Physician (Cardiology) Professor of Pharmacology and Therapeutics at two of Australia’s leading
universities) and the trial results were confirmed.

Second trial data

Peer reviewed published paper - from our 2021 trial

5e. We know Cavadex is absorbed into the blood stream when administered as an enema....

Cholrem Pty Ltd developed an enema version of Cavadex for home use.
The Remchol enema could supply a 25% absorption rate of Cavadex.

Cholrem Pty Ltd established an online store to commence limited sales of Remchol tubes containing Cavadex.

2022

5f. Cardiologists agree with the science and start treating themselves....

USA cardiologist Dr. James Roberts MD FACC FAARFM trialed Cavadex on himself with similar results.
He then went on and supplied his patients with Remchol tubes.

2023

5g. Patients around the world are reversing their heart disease with Cavadex....

Dr. Roberts reports all patients getting better and that Remchol-Cavadex reduced arterial plaque in his
patients without any adverse side-effects. He also reported several other benefits for stroke patients and brain fog.

Dr. Roberts published his data on his website

http://heartfixer.com/Cyclodextrin.htm


 

2024

Microplastics and Cyclodextrin: Exploring a New Frontier in Health

https://cholrem-cavadex.com/blogs/dr-james-roberts-talks-cavadex/microplastics-and-cyclodextrin-exploring-a-new-frontier-in-health
 

Files coming soon.

Copyright © 2025 Cavadex America - All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept